کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5826394 | 1120431 | 2012 | 6 صفحه PDF | دانلود رایگان |
In the past few years, intestinal microbiota has emerged as a novel target for the treatment of gut-brain axis alterations. These include functional gastrointestinal disorders, such as irritable bowel syndrome (IBS), which can be comorbid with stress-related psychiatric conditions. Thus, modulation of the microbiota (e.g. with the use of probiotics) could be proposed as a novel strategy not only for the treatment of IBS but also as an adjuvant for psychiatric treatment of anxiety and depression.
.210Highlights⺠Gut microbiota is a new target for the treatment of intestinal disorders. ⺠Modulation of microbiota has an impact on animal behaviour. ⺠Probiotics have important effects on gut and mental health. ⺠Intestinal microbiota could be a new target for mental illness. ⺠Probiotics could be novel adjuvant to psychiatric therapy.
Journal: Current Opinion in Pharmacology - Volume 12, Issue 6, December 2012, Pages 667-672